n-3 PUFA may reduce markers of kidney disease in T2DM

n-3 PUFA may reduce markers of kidney disease in T2DM
In patients with type 2 diabetes and evidence of kidney injury, supplementation with n-3 long-chain polyunsaturated fatty acids does not reduce urine albumin excretion but is associated with a reduction in certain markers of kidney injury, according to research published online Dec. 28 in Diabetes Care.

(HealthDay)—In patients with type 2 diabetes and evidence of kidney injury, supplementation with n-3 long-chain polyunsaturated fatty acids (PUFA) does not reduce urine albumin excretion but is associated with a reduction in certain markers of kidney injury, according to research published online Dec. 28 in Diabetes Care.

To examine the effect of n-3 PUFA supplementation on urine albumin excretion and markers of kidney injury, Edgar R. Miller III, M.D., Ph.D., of the Johns Hopkins School of Medicine in Baltimore, and colleagues conducted a randomized, placebo-controlled, two-period crossover trial involving 29 participants with type 2 diabetes and evidence of kidney disease who were given 4 g/day of n-3 PUFA supplements for six weeks.

The researchers found that n-3 PUFA supplementation resulted in non-significant reductions in urine albumin excretion compared with placebo, and correlated with significant reductions in urine neutrophil gelatinase-associated lipocalin (NGAL) excretion. There was no significant effect for n-3 PUFA on of or estimated . In the subgroup of participants taking medications that block the renin-angiotensin-aldosterone system, significant decreases were observed in 24-hour urinary albumin excretion, NGAL, liver fatty acid-binding protein, and N-acetyl β-D-glucosaminidase.

"n-3 PUFA failed to reduce the primary outcome of urine albumin excretion," the authors write. "However, there was a consistent trend of benefit for all urine biomarkers and a significant reduction in NGAL."

Lovaza (n-3 PUFA) and placebo used in the study were provided by GlaxoSmithKline.

More information: Abstract
Full Text (subscription or payment may be required)

add to favorites email to friend print save as pdf

Related Stories

Fatty acids don't reduce atrial fibrillation recurrence

Dec 21, 2012

(HealthDay)—Polyunsaturated fatty acids (n-3 PUFA) do not reduce the recurrence of atrial fibrillation (AF), according to a study published online Dec. 19 in the Journal of the American College of Cardiology.

Warning signs predict kidney injury after surgery

Aug 12, 2011

Acute kidney injury (AKI) is a common – but preventable -- complication after surgery that can lead to other complications or even death. The use and development of biomarkers will help physicians diagnose and treat ...

Recommended for you

Progress in diabetes drug delivery

Jan 22, 2015

A drug therapy for diabetes treatment is being developed by an international research team led by WA scientists, which combines an existing anti-diabetic drug with bile acids to improve the drug's delivery ...

Roux-en-Y surgery can reverse insulin treatment in T2DM

Jan 21, 2015

(HealthDay)—Roux-en-Y gastric bypass surgery (RYGB) strongly predicts insulin cessation after surgery in insulin-treated type 2 diabetes (I-T2D) patients, independent of weight loss, according to a study ...

Unexpected turn in diabetes research

Jan 20, 2015

Years of diabetes research carried out on mice whose DNA had been altered with a human growth hormone gene is now ripe for reinterpretation after a new study by researchers at KU Leuven confirms that the gene had an unintended ...

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.